Bristol Erbitux: Colorectal Refiling Within 9 Months; Broader Package In 2004

Bristol-Myers Squibb could refile Erbitux in irinotecan-refractory colorectal cancer by July, Exec VP Donald Hayden told the Bear Stearns healthcare conference in New York City Sept. 17